Stay updated on Nivolumab +/- Ipilimumab in NECs Clinical Trial
Sign up to get notified when there's something new on the Nivolumab +/- Ipilimumab in NECs Clinical Trial page.

Latest updates to the Nivolumab +/- Ipilimumab in NECs Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now indicates Revision: v3.3.2; the content shown (study details, criteria, and results) appears unchanged compared to the previous revision. No new content or functional changes are visible in the screenshot.SummaryDifference0.1%

- Check21 days agoChange DetectedThe page shows a revision update from v3.2.0 to v3.3.1, which does not alter any study data, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedA funding-status notice was removed from the page. The study details and eligibility information remain unchanged.SummaryDifference0.4%

- Check43 days agoChange DetectedNo additions or deletions detected; the page content appears unchanged between the two screenshots.SummaryDifference0.4%

- Check71 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference3%

- Check79 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

Stay in the know with updates to Nivolumab +/- Ipilimumab in NECs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab +/- Ipilimumab in NECs Clinical Trial page.